MedTrace Logo

Efficacy and Safety Evaluation of EASYEF® in Acute Wound (Split-thickness Skin Graft Donor Site)

NCT05335720 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-07-22

No results posted yet for this study

Summary

This study is a prospective study, randomized, using control, open-label, single-center to evaluate the efficacy and safety of EASYEF® in acute wound (split-thickness skin graft donor site). A total of 10 subjects are randomly allocated. Subjects who meet the final inclusion and exclusion criteria are randomized to the test cohorts in a ratio of 1:1:1.

Conditions

  • Skin Graft Scar
  • Split-Thickness Skin Graft (STSG)

Interventions

DRUG

rhEGF

EASYEF® spray 50 mcg, sprayed twice a day for 14 days.

Sponsors & Collaborators

  • Equilab International

    collaborator UNKNOWN

  • PT. Daewoong Infion

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-19
Primary Completion
2020-03-01
Completion
2020-04-08

Countries

  • Indonesia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05335720 on ClinicalTrials.gov